<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805934</url>
  </required_header>
  <id_info>
    <org_study_id>rjyyxhk2013-01</org_study_id>
    <nct_id>NCT01805934</nct_id>
  </id_info>
  <brief_title>Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection</brief_title>
  <official_title>Quadruple Therapy With Furazolidone Versus Dual Therapy With High Doses of Amoxicillin as Rescue Regimens for Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The eradication rates of first-line treatment for Helicobacter pylori(Hp) infection are not
      satisfactory. The study aims to compare the efficacy and safety between quadruple therapy
      with furazolidone and dual therapy with high doses of amoxicillin as rescue regimens for Hp.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>13C-urea breath test</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>When the outcome of 13C-urea breath test is more than 4%, the helicobacter pylori infection is still exist(positive).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>scale analysis of drug safety</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>13C-urea breath test</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Rescue Therapy for Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Group RBLF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group RA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBLF</intervention_name>
    <description>The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).</description>
    <arm_group_label>Group RBLF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RA</intervention_name>
    <description>The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).</description>
    <arm_group_label>Group RA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18 to 80 years, who presented with upper gastrointestinal symptoms
             and endoscopically proven H. pylori-positive non-ulcer dyspepsia, were recruited into
             the study.

        Exclusion Criteria:

          -  patients with peptic ulcer,

          -  previous H. pylori eradication treatment,

          -  previous gastric surgery,

          -  pregnancy,

          -  lactation,

          -  major systemic diseases,

          -  receipt of anti-secretory therapy,

          -  antibiotics or bismuth in the preceding four weeks, or - allergy to any one of the
             medications in the regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaobo Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Renji Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xiaobo Li</investigator_full_name>
    <investigator_title>Xiaobo Li</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori, rescue, quadruple therapyï¼Œdual therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

